Literature DB >> 20409870

Historical perspective of low- vs. high-dose diuretics.

Barry J Materson1.   

Abstract

In the 50 years since the introduction of cholorothiazide by Fries and Wilson for the treatment of hypertension, numerous thiazide and thiazide-like diuretics have been marketed. Orally-administered diuretics enhanced the therapeutic efficacy of extant antihypertensive medications and reduced the doses required; adverse effects were thereby reduced as well. Initially, high doses of diuretics were employed at least in part because of the misconception that substantial natriuresis was required for their antihypertensive effect. As the long-term vasodilating effects of the thiazides became appreciated, it was possible to separate antihypertensive dose-response from natriuretic dose-response. As ever lower doses of thiazides were proven to be effective, most of their associated biochemical side and adverse effects were also reduced. Fifty years later, thiazide diuretics maintain a key role in the treatment of hypertension-especially in combination with one or more non-diuretic drugs.

Entities:  

Year:  2007        PMID: 20409870     DOI: 10.1016/j.jash.2007.06.007

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  3 in total

1.  Guidelines for use of diuretics: a view from a member of JNC 7.

Authors:  Barry L Carter
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-11       Impact factor: 3.738

2.  Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-09-07       Impact factor: 3.738

3.  Pharmaceutical composition of hydrochlorothiazide:β-cyclo-dextrin: preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation.

Authors:  Maria Arlete Silva Pires; Robson Augusto Souza Dos Santos; Rubén Dario Sinisterra
Journal:  Molecules       Date:  2011-05-27       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.